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Abstract
Background: Early assessment of response to chemotherapy in acute myeloid leukemia may be performed by
examining bone marrow aspirate (BMA) or biopsy (BMB); a hypocellular bone marrow sample indicates adequate
anti-leukemic activity. We sought to evaluate the quantitative and qualitative assessment of BMA performed on day
14 (D14) of chemotherapy, to verify the inter-observer agreement, to compare the results of BMA and BMB, and to
evaluate the impact of D14 blast clearance on the overall survival (OS).
Methods: A total of 107 patients who received standard induction chemotherapy and had bone marrow samples
were included. BMA evaluation was performed by two observers using two methods: quantitative assessment and a
qualitative (Likert) scale. ROC curves were obtained correlating the BMA quantification of blasts and the qualitative
scale, by both observers, with BMB result as gold-standard.
Results: There was a significant agreement between the two observers in both the qualitative and quantitative
assessments (Kw = 0.737, p < 0.001, and rs = 0.798, p < 0.001; ICC = 0.836, p < 0.001, respectively). The areas under the
curve (AUC) were 0.924 and 0.946 for observer 1 and 0.867 and 0.870 for observer 2 for assessments of the
percentage of blasts and qualitative scale, respectively. The best cutoff for blast percentage in BMA was 6 % and
7 % for observers 1 and 2, respectively. A similar analysis for the qualitative scale showed the best cutoff as
“probably infiltrated”. Patients who attained higher grades of cytoreduction on D14 had better OS.
Conclusions: Evaluation of D14 BMA using both methods had a significant agreement with BMB and between
observers, identifying a population of patients with poor outcome.
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Background
The outcome of patients with acute myeloid leukemia
(AML) has improved substantially over the past decades,
thanks to the development of more aggressive therapies
and better supportive care. However, a substantial pro-
portion of patients still do not obtain complete remis-
sion (CR), and others eventually relapse after achieving
CR [1–3]. In an attempt to stratify subgroups with dif-
ferent survival rates, several prognostic factors have been
identified, including age, gender, baseline white blood
cell count, lactic dehydrogenase serum level, immuno-
phenotype, karyotypic abnormalities and genetic profiles
[4–7].
In addition to baseline variables, early assessment of
response to chemotherapy may help to define prognosis.
Previous studies have shown an association between the
lack of early blasts clearance and failure to obtain CR
after a first cycle of induction [8, 9]. This early assess-
ment of treatment response is usually performed be-
tween the 14th (D14) and 17th day of the first cycle of
induction chemotherapy, by analyzing the cellular con-
tent of the bone marrow aspirate (BMA) and/or biopsy
(BMB). A hypocellular bone marrow sample suggests
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adequate anti-leukemic activity [8, 10]. However, its in-
terpretation may be inaccurate because of different levels
of expertise among pathologists and hematologists, and
a great variability in BMA and BMB sample quality [11].
Furthermore, a BMA blast count above which poor re-
sponse to chemotherapy is predicted has not been
clearly defined, with values ranging from 5 % to 40 %
[8–19]. By contrast, the BMB provides a better assess-
ment of marrow cellularity [20], but the results are avail-
able only a few days after the BMA, delaying the
decision to administer a second course of induction
chemotherapy for non-responders.
Given these uncertainties, we sought to evaluate the
quantitative and qualitative assessment of D14 BMA, to
verify the inter-observer agreement, and to compare the
results of BMA and BMB. We also assessed the impact
of D14 blast clearance on the overall survival (OS).
Methods
Study population and treatment
All patients diagnosed with AML at University Hospital
Clementino Fraga Filho, Universidade Federal do Rio de
Janeiro (UFRJ) Brazil, from January 1979 to December
2008 were retrospectively evaluated. Entry criteria for
this study included: a diagnosis of AML other than acute
promyelocytic leukemia, no previous treatment in other
institution, receipt of standard induction chemotherapy
(cytarabine + antracycline), and performance of BMA on
D14 of induction chemotherapy. The study was
approved by the local ethics committee (Hospital Clem-
entino Fraga Filho/Universidade Federal do Rio de
Janeiro, CAAE n°. 0094.0.197.000-09) and was con-
ducted in accordance with the principles of Helsinki
declaration. Informed consent was not obtained due to
its retrospective nature of this study did not affect the
healthcare of the included individuals. Moreover, confi-
dentiality was preserved.
The diagnosis of AML was based on available proce-
dures at the time, including BMA and BMB, and cyto-
genetic and immunophenotype analyses. Cases were
classified according to de French-American-British
(FAB) criteria [21]. The treatment regimens changed
over time (Table 1) [22].
Bone marrow aspirate and biopsy
Routine assessments of BMA and BMB were performed
on D14 of induction remission. Aspirate smears were
prepared at the bedside and stained with Wright-Giemsa
stain, and biopsy samples were fixed in 10 % buffered
formalin, and stained with hematoxylin and eosin.
Patients with persistent disease according to D14 assess-
ment received a second cycle of induction as early as
possible [2, 13]. All glass slides were kept in storage
units in the hospital achieves.
Table 1 Different approaches to the treatment of acute
myeloid leukemia between time periods
Time periods Treatment
Induction Remission:
Until 1985 TAD protocol:
- Thioguanine 100 mg/m2 orally every 12 hours for
7 days
- Cytarabine 100 mg/m2/d iv for 7 days
- Doxorubicin 30 mg/m2/d iv for 3 days
After 1985 7 + 3 protocol:
- Cytarabine 200 mg/m2/d iv for 7 days
- Daunorubicin 45 mg/m2/d or doxorubicin 30 mg/m2
iv for 3 days
Residual
leukemia
5 + 2 protocol:
- Cytarabine 200 mg/m2/d iv for 5 days
- Daunorubicin 45 mg/m2/d or doxorubicin 30 mg/m2/
d iv for 2 days
Post-remission treatment:
Until 1985 12 maintenance cycles of TAD
1986 to 1992 4 courses:
- Cytarabine 400 mg/m2/d iv for 3 days
- Doxorubicin 30 mg/m2/d iv for 3 days
1993 to 1998 2-4 courses:
- High-dose cytarabine 1 g/m2 iv every 12 hours for
4 days
- Doxorubicin 30 mg/m2/d iv for 3 days
After 1999 2-4 courses:
- High-dose cytarabine 3 g/m2 iv every 12 hours on
days 1, 3 and 5
iv intravenous infusion
Table 2 Agreement and comparison of frequency between
















13 4 2 2 0 21
Probably
free
17 6 3 7 2 35
Doubtful 0 6 3 1 1 11
Probably
infiltrated
1 0 4 9 5 19
Definitely
infiltrated
0 0 0 3 18 21
Total 31 16 12 22 26 107
Quadratic weighted kappa coefficient: Kw = 0.74, 95 % CI 0.64-0.83, p < 0.001)
Modified McNemar test: X2 = 0.28, p = 0.8
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We reviewed all available slides from BMA performed
at diagnosis and on D14. The analysis was performed by
two independent observers (board certified hematolo-
gists), blinded for patient identification and outcome.
The evaluation included confirmation of the initial diag-
nosis of AML and identification of D14 residual
leukemia in a quantitative (percentage) and qualitative
(scale) manner. Quantitative evaluation was performed
by counting the percentage of blasts in 200 nucleated
marrow cells. The qualitative assessment was deter-
mined by stratification in a Likert scale [23] of five
categories: definitely infiltrated, probably infiltrated,
doubtful, probably free and definitely free.
The results of D14 BMB were obtained by reviewing
patients’ medical records and registries from the Path-
ology Service of the hospital. The reports were catego-
rized as aplastic (leukemia free) or infiltrated.
Statistical analysis
The qualitative assessment of blasts was first treated as
an ordinal categorical variable and latter grouped in two
categories, and treated as dichotomous categorical
variable. Agreement between the two observers was
assessed using the kappa coefficient (Cohen’s kappa) and
quadratic weighted kappa coefficient (Kw). The kappa
coefficient may range from −1 (complete disagreement)
Fig. 1 Qualitative assessment of bone marrow aspirates on D14 induction chemotherapy in AML patients. a and b: definitely free; c and d:
doubtful; e and f: definitely infiltrated (Wright-Giemsa, x400 and x1000, respectively)
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to +1 (complete agreement) and the correlation is
usually classified as poor (below 0), mild (0 to 0.2), low
(0.21 to 0.4), moderate (from 0.41 to 0.6) substantial
(0.61 to 0.8) and almost perfect (0.81 to 1.00) [24].
Further evaluation of the marginal homogeneity of pro-
portions was performed with the McNemar test for
dichotomous categorical variables and the McNemar
modified test for ordinal categorical variables. In both
tests, the presence of a significant p value (<0.05) indi-
cates excessive variation between observers [25].
The quantitative assessment of blasts was treated as
a discrete variable with a non-normal distribution;
comparisons between observers were performed with
Spearman’s Correlation Coefficient (rs). Measurements
between observers were also compared using Intra-
class Correlation Coefficient (ICC) and the Bland and
Altman method [26].
The D14 BMA evaluation was compared with the
BMB (considered as “gold standard”) using receiver
operating characteristic (ROC) curves to assess the
best cut-off point in terms of sensitivity, specificity
and accuracy. The areas under the ROC curves (AUC)
were compared using the method of Delong [27]. OS
was defined as the time from diagnosis to death of any
cause or last follow-up. Survival curves were estimated
with the Kaplan-Meier method and differences were
compared with the log-rank test. Multivariate analysis
for OS was conducted using a Cox model and hazard ratios
(HR) were obtained for each observer. All tests were 2-
sided, and p values <0.05 were considered statistically sig-
nificant. Statistical analyses were performed using SPSS




Of 295 patients with AML identified in the hospital
records, 119 fulfilled entry criteria. Among these 119
patients who had a BMA on D14, we could recover
107 sets of BMA smears, containing samples of the
diagnosis and D14 assessment. The median age was
38 years (range 12–77), 12 % were >60 years-old and
58 % were males. In addition, we were able to compare
D14 BMA and BMB in 82 patients.
Agreement analysis between observers
The comparisons between observers of D14 BMA
evaluation using the qualitative scale is shown in
Table 2. The quadratic weighted kappa coefficient was
0.74 (95 % confidence interval [95 % CI] 0.64 - 0.83, p
< 0.001), and no bias was observed (p = 0.8, modified
McNemar test). Typical qualitative categories are
shown in Fig. 1.
The median blast count on D14 was 4 % and 6 % for
observers 1 and 2, respectively, with a Spearman correl-
ation coefficient of 0.798 (p <0.001) (Fig. 2), and an
ICC within assessments of 0.836 (95 % CI 0.768 - 0.885,
p < 0,001). The average difference between measure-
ments of the percentage of blasts among the observers,
according to the Bland and Altman method, was 5.01 %
(95 % CI 7.63 - 2.39).
Comparison of bone marrow aspiration and bone marrow
biopsy on D14
The evaluation of BMB on D14 showed 33 patients
with bone marrow infiltration and 49 free of leukemia.
Table 3 shows the distribution of the categories of the
qualitative scale according to the BMB status. We
observed an association between the categories of def-
initely free and probably free with leukemia free in the
BMB, and the categories of definitely infiltrate and
Table 3 Correlation of BMA evaluation by both observers using
the Likert scale with the results of the BMB
BMB - observer 1 BMB - observer 2
n = 82 n = 82
BMA aplasia infiltrated aplasia infiltrated
n (%) n (%) n (%) n (%)
Definitely free 27 (32.9) 0 (0.0) 16 (19.5) 1 (1.2)
Probably free 14 (17.1) 2 (2.4) 23 (28.0) 5 (6.1)
Doubtful 4 (4.9) 2 (2.4) 7 (8.5) 4 (4.9)
Probably infiltrated 3 (3.7) 13 (15.9) 1 (1.2) 9 (11.0)
Definitely infiltrated 1 (1.2) 16 (19.5) 2 (2.4) 14 (17.1)
BMB bone marrow biopsy, BMA bone marrow aspirate
Fig. 2 Correlation between the percentage of blasts in D14 bone
marrow aspirate by two observers
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probably infiltrated with infiltrated BMB (85.4 % for
observer 1 and 75.6 % for observer 2). Doubtful results
of BMA represented mainly leukemia free BMB for
both observers.
Figure 3 shows the ROC curves correlating the BMA
quantification of blasts and qualitative scale, by both
observers, according to BMB results. The AUCs for
the quantitative and qualitative assessments were
0.924 and 0.946 for observer 1, and 0.867 and 0.870
for observer 2, respectively. We also compared the
ROC curves of the quantitative and qualitative analysis
of each observer. The difference in AUCs was 0.025
for observer 1 (p = 0.22) and 0.002 for observer 2 (p =
0.97).
Determining the best cut-off points
The best cut-off points for blast percentage in BMA
was 6 % for observer 1 (AUC 0.883, 84.9 % sensitivity,
91.8 % specificity, and 89.9 % accuracy), and 7 % for
observer 2 (AUC 0.858, 81.8 % sensitivity, 89.8 % spe-
cificity, and 86.6 % accuracy). A similar analysis for
the Likert scale showed the best cutoff point as the
4th item of the scale (probably infiltrated) for both
observers: AUC 0.898, 87.9 % sensitivity, 91.8 % speci-
ficity, and 90.2 % accuracy for observer 1, and AUC
0.818, 69.7 % sensitivity, 93.9 % specificity, and 84.1 %
accuracy for observer 2.
Based on the best cut-off point of qualitative assess-
ment, we divided the five categories of the scale in
two: “free” and “infiltrated”. The first represents the
grouping of categories definitely free, probably free
and doubtful, while the second included the categories
probably infiltrated and definitely infiltrated. The
kappa coefficient for the comparison between ob-
servers was 0.66 (95 % CI 0.51 - 0.80, p < 0.001), with
no bias per McNemar test (p = 0.1) (Table 4).
Impact of D14 blasts on survival
Five-year OS was significantly longer in patients with
<5 % blasts on D14 for both observers (Fig. 4). With
Likert scale, a better outcome in patients with lower
grades of marrow involvement was also observed
(Fig. 5). The same results were obtained among 55
Fig. 3 ROC curves of the quantitative and qualitative evaluations of D14 BMA by two observers
Table 4 Agreement and comparison of frequency between
grouped categories of the Likert scale between two observers
Observer 1
Observer 2 Free* Infiltrated** Total
Free* 54 14 68
Infiltrated** 4 35 39
Total 58 49 107
*definitely free, probably free and doubtful; **probably infiltrated and
definitely infiltrated
Kappa (K = 0.66, 95 % CI 0.51 - 0.80, p < 0.001)
McNemar (X2 = 2.28, p = 0.1)
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patients in CR who received two or more cycles of
intensification (Fig. 6). Other variables detected as
prognostic factors by univariate analysis were: age
>60 years, year of diagnosis, treatment delay >7 days
from diagnosis, presence of comorbidities, previous
cardiac disease, hepatomegaly, active bleeding, gastro-
intestinal infection and FAB subtype M2 (p <0.05)
(Table 5).
Predictors of poor outcome (lower OS) by multivari-
ate analysis, with HR obtained respectively for ob-
servers 1 and 2, were age >60 years [HR = 4.67 (95 % CI
1.91-11.4) and 4.36 (95 % CI 1.79-10.61)], the presence
of active bleeding at diagnosis [HR = 2.37 (95 % CI
1.18-4.74) and 2.05 (95 % CI = 1.01-4.13)] and residual
D14 blasts with Likert scale [HR = 1.42 (95 % CI 1.11-
1.81) and 1.43 (95 % CI = 1.11-1.92)] (Table 6).
Discussion
In this study we found substantial agreement between
observers using two different methods: a quantitative
assessment, with the determination of the percentage
of bone marrow blasts, and a qualitative, based on the
perception of marrow infiltration. In addition, a cutoff
value of 6-7 % of blasts in the quantitative assessment
and “probably infiltrated” marrow in the qualitative
assessment was established, with good discriminatory
power to identify patients with infiltrated BMB. More-
over, we observed a higher OS in patients who ob-
tained higher grades of cytoreduction by day 14
marrow evaluation.
While risk assessment in AML relies mainly on age
and cytogenetic profile [5], the assessment of in vivo
chemosensitivity by determining early response to
induction therapy is an additional predictive marker.
Indeed, this parameter has been used to guide clini-
cians in deciding for an early second cycle of chemo-
therapy [13, 28, 29]. However, the type of D14 bone
marrow evaluation (BMA, BMB or both) has varied,
with some studies relying on BMA [8, 16], others used
BMB [18], and occasionally no clear information was
provided [9, 10, 17, 19].
In our study we observed that the qualitative and the
quantitative methods were equally predictive of BMB
results, with a substantial inter-observer agreement.
Bone marrow evaluation by more than one observer has
been previously reported [16, 17], but to our best know-
ledge, our study was the first that reported the assess-
ment of inter-observer agreement.
Another point of controversy is the cutoff values of blast
cell percentage in the quantitative assessment of BMA.
Different studies have established cutoff values that ranged
from 5 % [9, 10, 30, 31], 10 % [8, 9, 17], 15-22 % [16], and
even 40 % [10]. These variations are also present in pub-
lished Guidelines: <5 % [11], <5-10 % [12], <10-15 % [13]
and hypoplasia or aplasia (without defining a numerical
value) [14]. We established a cutoff value of 6-7 % (inter-
observer variation), which is in the range of previous stud-
ies, and identified that the qualitative categories of definitely
and probably infiltrated were predictive of residual
leukemia on BMB.
All analyzes of response assessment by D14 BMA by both
methods (qualitative and quantitative) and both observers
resulted in higher specificity than sensitivity. Likewise, the
concordance between observers was very good for “defin-
itely/probably infiltrated”, but not so good for “definitely/
probably free”. Therefore, there is no debate that a large
Fig. 4 Overall survival according to the quantitative evaluations of D14 BMA by two observers
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amount of leukemic blast on day 14 constitutes un-
equivocal evidence of residual leukemia. However, the
presence of a few blasts in a paucicellular or hemodi-
lute marrow sample cannot be considered as definite
evidence of residual disease. Indeed, most guidelines
determine a second induction cycle for unequivocal
residual disease and most dilemmas occurs in patients
with low blast count (5-15 %) [32].
Few previous studies have shown an association be-
tween D14 marrow findings and long-term outcome
[8, 9, 10, 17, 30]. In the present study, multivariate
analysis showed that the evaluation of the bone mar-
row infiltration by Likert scale (but not the percentage
assessment) was significantly associated with poor
outcome.
Our study shares the limitations of all retrospective
studies. It was not possible to recover D14 BMA and
BMB slides from all cases. In addition, survival ana-
lysis was performed without the inclusion of well-
known prognostic factors such as chromosomal and
Fig. 5 Overall survival according to the qualitative evaluations of D14 BMA by two observers
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Fig. 6 Overall survival according to the qualitative evaluations of D14 BMA by two observers in patients (n = 55) treated with two or more cycles
of intensification
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molecular abnormalities. Finally, we did not analyze
the potential effect of the different induction regimens
given throughout the study period and the number of
entry-patients over the study period. Despite these
limitations, we were able to show that BMA may be
considered the procedure of choice to assess treatment
response on D14 because it provides results immedi-
ately, and exhibited good agreement between ob-
servers and good correlation with BMB and OS.
Conclusions
We conclude that the assessment of BMA on day 14th
of remission induction chemotherapy in patients with
AML is a reproducible test with a substantial agree-
ment between observers, both quantitatively and
qualitatively, has good correlation with BMB and with
OS. The percent cut-off 6-7 % or “probably infiltrated”
may help to early identify a population of patients with
unfavorable prognosis.
Table 5 Factors associated with poor outcome (overall survival)
in patients with acute myeloid leukemia by univariate analysis
Variable HR 95.0 % CI P value
Age > 60 years 1.685 1.203 2.362 0.002
Male gender 1.068 0.799 1.428 0.66
Year of treatment 1.317 1.096 1.582 0.003
Treatment delay > 7 days from diagnosis 1.551 1.031 2.333 0.03
Comorbidities
Cardiac disease 1.534 1.082 2.174 0.02
Lung disease 1.924 0.937 3.95 0.07
Liver disease 0.880 0.326 2.372 0.80
Kidney disease 2.648 0.976 7.184 0.06
Diabetes 1.371 0.744 2.528 0.31
At least one comorbidity 1.596 1.153 2.211 0.005
MDS-related AML 1.338 0.904 1.979 0.15
Initial clinical manifestations
Fever 1.265 0.928 1.725 0.14
Gingival hyperplasia 1.268 0.881 1.825 0.20
Lymphadenomegaly 0.867 0.644 1.166 0.34
Hepatomegaly 1.793 1.339 2.400 0.001
Splenomegaly 1.365 0.991 1.88 0.06
Pulmonary involvement 0.668 0.166 2.693 0.57
Cutaneous involvement 0.790 0.404 1.544 0.49
CNS involvement 0.475 0.066 3.401 0.46
Active bleeding 1.589 1.189 2.123 0.002
DIC 0.606 0.225 1.635 0.32
Infection at diagnosis
Pharyngitis 1.139 0.691 1.876 0.61
Gastrointestinal 2.842 1.439 5.614 0.003
Fever of unknown origin 1.096 0.761 1.578 0.62
Blood 0.632 0.201 1.982 0.43
Skin and soft tissue 0.877 0.575 1.337 0.54
Pneumonia 1.490 0.995 2.23 0.05
Sinusitis 0.392 0.055 2.799 0.35
Oral cavity 0.775 0.462 1.298 0.33
Urinary tract 0.994 0.408 2.421 0.99
At least one infection 1.142 0.843 1.548 0.39
FAB classification
M0 0.563 0.203 1.560 0.27
M1 0.747 0.367 1.520 0.42
M2 0.524 0.339 0.809 0.004
M4 0.796 0.539 1.177 0.25
M5 1.560 0.963 2.528 0.71
M6 0.888 0.321 2.461 0.82
M7 1.294 0.554 3.025 0.55
Laboratory abnormalities
Table 5 Factors associated with poor outcome (overall survival)
in patients with acute myeloid leukemia by univariate analysis
(Continued)
Leukocytes 1.000 1.000 1.00 0.13
Neutrophils 0.994 0.985 1.003 0.21
Hemoglobin 1.007 0.981 1.034 0.60
Platelets 1.001 0.999 1.002 0.22
Neutropenia 1.049 0.775 1.419 0.76
Leukocytosis (≥50 × 109/L) 1.220 0.890 1.673 0.22
LDH 1.000 1.000 1.001 0.07
% blasts D14 (observer 1) 1.018 1.009 1.027 0.001
% blasts D14 (observer 2) 1.014 1.007 1.022 0.001
Likert scale D14 (observer 1) 1.197 1.032 1.387 0.02
Likert scale D14 (observer 2) 1.339 1.147 1.563 0.001
HR hazard ratio, 95 % CI 95 % confidence interval, CNS central nervous system,
DIC disseminated intravascular coagulation FAB French–American–British, LDH
lactate dehydrogenase
Table 6 Factors associated with poor outcome (overall survival)
in patients with acute myeloid leukemia by multivariate analysis
performed with D14 BMA evaluation by both observers
Observer 1 Observer 2
Variable HR 95.0 % CI P HR 95.0 % IC P







0.01 2.052 1.018 - 4.135 0.04
Likert scale
D14
1.425 1.118 -1.816 0.004 1.463 1.114 -1.922 0.006
All variables associated with univariate P-value <0.05 were included in the
multivariate analysis. Only independent parameters are shown. HR hazard
ratio; 95 % CI 95 % confidence interval
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